Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report

Sonia Gupta; Amandeep Rakhra; Vinay Thallapally; Joseph Nahas

doi:10.5582/irdr.2020.03144

This article has now been updated. Please use the final version.

Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report

Sonia Gupta, Amandeep Rakhra, Vinay Thallapally, Joseph Nahas

Author information

Keywords: anti-HMGCR, immune-mediated necrotizing myopathy, immunosuppressants, rituximab

JOURNAL FREE ACCESS Advance online publication

Article ID: 2020.03144

DOI https://doi.org/10.5582/irdr.2020.03144

The final version of this article is now available: Vol. 10 (2021), No. 2 pp. 122-125

Details

Abstract

Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab is more limited in this type of myopathy. Reported here is a case of a patient who responded well to rituximab (RTX) after the standard immunosuppressants had failed. This case illustrates the importance of further studies to evaluate the role of RTX in anti-HMGCR myopathy.

Corresponding author

Register with J-STAGE for free!